Pacts In Medtech, September/October 2016
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deal activity, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in July and August 2016.
You may also be interested in...
Market Intel: Ever Decreasing Dimensions, Snakes And Origami: The Next-Gen Surgical Robots
From "smart" snake-like catheters to miniscule-sized devices, a new generation of surgical robots, developed at world-renowned research institutions, aims to explore a new frontier by allowing doctors to target inaccessible areas within the body, and treat conditions with greater precision and better patient outcomes. With the surgical robotics market projected to surpass $10bn by 2021, a growing number of companies are hoping to capture their share in this trending space.
Deals In Depth: May 2022
In the top May alliance by deal value, Amphista Therapeutics and Bristol Myers Squibb aim to discover and develop targeted small-molecule protein degraders by leveraging Amphista's proprietary Eclipsys platform. BMS gets exclusive global rights to resulting products. Amphista will receive a $30M upfront payment, up to $1.25B in performance-based milestone payments, payment for a limited expansion of the collaboration, as well as royalties on global net sales.
Deals In Depth: April 2022
In the top April alliance by deal value, Jazz Pharmaceuticals acquired exclusive global development and commercialization rights to Werewolf Therapeutics' WTX-613. Preclinical WTX-613 is an engineered IFN⍺2b cytokine pro-drug that is activated specifically within the tumor microenvironment where it can stimulate IFNα receptors on cancer-fighting immune effector cells. Jazz expects to submit an IND application to the FDA for WTX-613 in 2023. Jazz paid $15M up front and Werewolf is eligible to receive development, regulatory and commercial milestone payments of up to $1.26bn, plus royalties.